Advertisement

Interferon Alpha-2: Pre-Clinical and Clinical Evaluation

Proceedings of the Symposium held in Adjunction with the Second International Conference on Malignant Lymphoma, Lugano, Switzerland, June 13, 1984

  • Daniel L. Kisner
  • J. F. Smyth
Book

Part of the Developments in Oncology book series (DION, volume 27)

Table of contents

  1. Front Matter
    Pages I-XI
  2. P. P. Trotta
    Pages 13-27
  3. C. E. Welander, H. B. Muss, T. M. Morgan, P. P. Trotta, R. J. Spiegel
    Pages 29-39
  4. D. Kisner
    Pages 41-42
  5. R. J. Spiegel
    Pages 43-49
  6. J. Wagstaff, D. Crowther, R. C. F. Leonard, J. F. Smyth, H. Host, N. C. Gorin
    Pages 51-56
  7. R. D. Leavitt, S. Kaplan, E. Bonnem, M. Grimm, H. Ozer, C. Portlock et al.
    Pages 57-73
  8. J. Costanzi, M. R. Cooper, J. H. Scarffe, H. Ozer, R. B. Pollard, R. W. Ferraresi et al.
    Pages 75-85
  9. H. M. Golomb, M. J. Ratain
    Pages 87-92
  10. J. F. Smyth
    Pages 99-106
  11. J. F. Smyth
    Pages 107-111

About this book

Introduction

Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone extensive phase I and phase II clinical study in more than 1000 patients. The material has biological activity by intravenous, intramus­ cular and subcutaneous routes. Clinical toxicity principally involves the 'influen­ za like' syndrome previously seen with native interferons. Other important toxi­ cities include anorexia, hepatitis, confusion and myelosuppression. Tolerable doses in multiple schedules and routes of administration have been determined. Phase II clinical trials with multiple routes and schedules of administration have been performed. Significant clinical activity has been found in non­ Hodgkin's lymphomas (both low grade and high grade), refractory and relapsing multiple myeloma, hairy cell leukemia, Kaposi's sarcoma, with suggestions of activity in Hodgkin's disease, renal cell carcinoma, and melanoma. The studies performed to date have for the most part involved small numbers of heavily pre-treated patients. Large-scale clinical trials in some of these disea­ ses are now warranted in populations of patients with as little bulk disease and prior treatment as is feasible for each tumour type. This is particularly the case in . Hodgkin's disease and subcategories of the non-Hodgkin's lymphomas. Alterna­ tely, interferon alpha-2 might be used to maintain remissions induced by other modalities (i. e. , in NHL, multiple myeloma, ovarian cancer). In some advanced disease settings, combinations of interferon alpha-2 with chemotherapeutic agents should now be investigated.

Keywords

DNA carcinoma cell clinical trial interferon leukemia lymphoma melanoma ovarian cancer renal cell carcinoma tumor

Editors and affiliations

  • Daniel L. Kisner
    • 1
  • J. F. Smyth
    • 2
  1. 1.Dept. of Medicine, Div. of OncologyUniversity of Texas Health Science Center at San AntonioSan AntonioUSA
  2. 2.Dept. of Clinical OncologyUniversity of Edinburgh Western General HospitalEdinburghScotland

Bibliographic information

Industry Sectors
Pharma
Health & Hospitals
Biotechnology
Oncology & Hematology